keynote-716: safety profile and results of pembrolizumab for melanoma
Published 2 years ago • 108 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
2:18
keynote-716: longer follow up supports pembrolizumab use in stage iib/iic melanoma
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
6:52
expert report on novel data in (neo)adjuvant treatment of melanoma from asco 2022
-
2:19
#esmo21 highlights on pembrolizumab in fully resected high-risk stage ii melanoma: keynote-716 study
-
0:48
final analysis of distant metastasis-free survival in the keynote-716 study
-
5:12
long-term safety of pembrolizumab for advanced melanoma
-
1:30
adjuvant therapy for high-risk melanoma
-
2:25
efficacy of pembrolizumab treatment in mucosal melanoma
-
10:36
results of keynote-054; melanoma patients treated with pembrolizumab
-
2:31
pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma
-
7:19
keynote-555: pembrolizumab bioavailability after subcutaneous administration in melanoma
-
9:40
reducing recurrence of advanced melanoma with pembrolizumab
-
3:35
keynote-006: the efficacy of ipilimumab after pembrolizumab in patients with advanced melanoma
-
5:01
melanoma highlights from esmo 2021
-
1:46
safety and preliminary evidence for efficacy for propranolol pembrolizumab in metastatic melanoma